SG10201914132RA - Anti-cd40 antibodies and their uses - Google Patents

Anti-cd40 antibodies and their uses

Info

Publication number: SG10201914132RA
Authority: SG; Singapore
Prior art keywords: antibodies
Prior art date: 2016-05-27

Application number

SG10201914132RA

Other languages

English (en)

Inventor

Diane Hollenbaugh

Shiming Ye

Diane Sau Mun COHEN

Original Assignee

Abbvie Biotherapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-27

Filing date

2017-05-26

Publication date

2020-03-30

2017-05-26 Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc

2020-03-30 Publication of SG10201914132RA publication Critical patent/SG10201914132RA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG10201914132RA 2016-05-27 2017-05-26 Anti-cd40 antibodies and their uses SG10201914132RA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662342417P	2016-05-27	2016-05-27

Publications (1)

Publication Number	Publication Date
SG10201914132RA true SG10201914132RA (en)	2020-03-30

Family

ID=59014833

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201810522UA SG11201810522UA (en)	2016-05-27	2017-05-26	Anti-cd40 antibodies and their uses
SG10201914132RA SG10201914132RA (en)	2016-05-27	2017-05-26	Anti-cd40 antibodies and their uses

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201810522UA SG11201810522UA (en)	2016-05-27	2017-05-26	Anti-cd40 antibodies and their uses

Country Status (34)

Country	Link
US (8)	US10519243B2 (es)
EP (2)	EP3464361B1 (es)
JP (2)	JP2019523221A (es)
KR (2)	KR102366355B1 (es)
CN (1)	CN109476750B (es)
AR (2)	AR108611A1 (es)
AU (1)	AU2017271602A1 (es)
BR (1)	BR112018074468A2 (es)
CA (1)	CA3025347A1 (es)
CL (1)	CL2018003366A1 (es)
CO (1)	CO2018012699A2 (es)
CR (1)	CR20180605A (es)
CY (1)	CY1124806T1 (es)
DO (1)	DOP2018000258A (es)
EC (1)	ECSP18094829A (es)
ES (1)	ES2901722T3 (es)
HR (1)	HRP20211882T1 (es)
HU (1)	HUE056670T2 (es)
IL (1)	IL263223B2 (es)
LT (1)	LT3464361T (es)
MX (1)	MX2018014630A (es)
MY (1)	MY195442A (es)
NZ (1)	NZ748644A (es)
PE (1)	PE20190970A1 (es)
PH (1)	PH12018502456A1 (es)
PL (1)	PL3464361T3 (es)
PT (1)	PT3464361T (es)
RS (1)	RS62726B1 (es)
RU (1)	RU2752049C2 (es)
SG (2)	SG11201810522UA (es)
SI (1)	SI3464361T1 (es)
TW (2)	TWI814279B (es)
UA (1)	UA123111C2 (es)
WO (1)	WO2017205742A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2704422C (en) *	2007-11-01	2019-09-24	The Board Of Trustees Of The University Of Arkansas	Compositions and methods of enhancing immune responses to eimeria
CN109476750B (zh)	2016-05-27	2022-02-01	艾伯维生物制药股份有限公司	抗cd40抗体及其用途
US11976123B2 (en)	2018-04-20	2024-05-07	Lyvgen Biopharma Holdings Limited	Anti-CD40 antibodies and uses thereof
WO2020104690A1 (en)	2018-11-23	2020-05-28	Quine Medical Ab	Bi-specific conjugates
KR20210099027A (ko) *	2018-11-30	2021-08-11	지앙수 헨그루이 메디슨 컴퍼니 리미티드	항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도
CN109912717B (zh) *	2019-03-04	2020-05-26	北京天广实生物技术股份有限公司	结合cd40的抗体及其用途
WO2020193718A1 (en)	2019-03-27	2020-10-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Recombinant proteins with cd40 activating properties
TW202103733A (zh) *	2019-04-10	2021-02-01	南開大學	抗cd40抗體及其用途
EP4027998A1 (en)	2019-09-09	2022-07-20	Basilea Pharmaceutica International AG	Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
WO2021048595A1 (en) *	2019-09-11	2021-03-18	Novartis Ag	A method for preventing human virus associated disorders in patients
EP4056592A4 (en) *	2019-11-08	2024-03-20	Jiangsu Simcere Pharm Co Ltd	ANTIBODY AGAINST HUMAN PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) AND USE THEREOF
EP4069291A1 (en) *	2019-12-03	2022-10-12	Evotec International GmbH	Interferon-associated antigen binding proteins and uses thereof
GB202008003D0 (en)	2020-05-28	2020-07-15	Quine Medical Ab	Anti-CD40 antibody
US20230346966A1 (en) *	2020-07-23	2023-11-02	Dyne Therapeutics, Inc.	Muscle-targeting complexes and uses thereof in treating muscle atrophy
CN115403670A (zh) *	2021-05-26	2022-11-29	安徽瀚海博兴生物技术有限公司	抗cd40抗体及其用途
WO2024059899A1 (en) *	2022-09-20	2024-03-28	Currus Biologics Pty Ltd	Bispecific polypeptides and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
EP1690934A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
CA2089661C (en)	1990-08-29	2007-04-03	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es)	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5885793A (en)	1991-12-02	1999-03-23	Medical Research Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
ATE390933T1 (de)	1995-04-27	2008-04-15	Amgen Fremont Inc	Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
CA2219486A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
EP0942968B1 (en)	1996-12-03	2008-02-27	Amgen Fremont Inc.	Fully human antibodies that bind EGFR
CA2286879C (en)	1997-04-14	2003-12-16	Peter Kufer	Novel method for the production of anti-human antigen receptors and uses thereof
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
AU1728800A (en)	1998-11-18	2000-06-05	Genentech Inc.	Antibody variants with higher binding affinity compared to parent antibodies
US6946129B1 (en) *	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
JP2003524644A (ja)	2000-02-01	2003-08-19	タノックスインコーポレイテッド	Ｃｄ４０−結合性ａｐｃ−活性化分子
US20030059427A1 (en) *	2000-04-28	2003-03-27	Force Walker R.	Isolation and characterization of highly active anti-CD40 antibody
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4242388B2 (ja) *	2003-12-25	2009-03-25	協和発酵キリン株式会社	抗ｃｄ４０抗体の変異体
WO2005123780A2 (en)	2004-04-09	2005-12-29	Protein Design Labs, Inc.	Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US20080287309A1 (en) *	2004-07-10	2008-11-20	Alexion Pharmaceuticals, Inc.	Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
EP1810035A4 (en)	2004-11-10	2010-03-17	Macrogenics Inc	EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS
US20090074711A1 (en)	2006-09-07	2009-03-19	University Of Southhampton	Human therapies using chimeric agonistic anti-human cd40 antibody
JP5401314B2 (ja) *	2006-09-08	2014-01-29	メディミューン，エルエルシー	ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
AU2008311365B2 (en) *	2007-10-05	2015-03-12	Ac Immune S.A.	Humanized antibody
EA031872B1 (ru) *	2010-03-31	2019-03-29	Бёрингер Ингельхайм Интернациональ Гмбх	Гуманизированное антитело к cd40, его применение, фармацевтическая композиция, содержащая это антитело, и выделенный полинуклеотид, кодирующий его
KR20190122889A (ko)	2011-04-29	2019-10-30	아펙시젠, 인코포레이티드	항-cd40 항체 및 사용 방법
GB201115280D0 (en) *	2011-09-05	2011-10-19	Alligator Bioscience Ab	Antibodies, uses and methods
TW202340236A (zh) *	2012-08-24	2023-10-16	日商中外製藥股份有限公司	FcγRIIb特異性Fc區域變異體
CN109265552A (zh) *	2012-10-30	2019-01-25	埃派斯进有限公司	抗-cd40抗体及其使用方法
MX368665B (es) *	2013-03-15	2019-10-10	Abbvie Biotherapeutics Inc	Variantes de fc.
GB201322583D0 (en) *	2013-12-19	2014-02-05	Alligator Bioscience Ab	Antibodies
CN107073118B (zh)	2014-10-29	2022-03-01	西雅图基因公司	非岩藻糖基化抗cd40抗体的剂量和给药
PT3303395T (pt) *	2015-05-29	2020-02-20	Abbvie Inc	Anticorpos anti-cd40 e usos dos mesmos
TW201806972A (zh) *	2016-05-27	2018-03-01	美商艾伯維生物醫療股份有限公司	雙特異性結合蛋白
CN109476750B (zh) *	2016-05-27	2022-02-01	艾伯维生物制药股份有限公司	抗cd40抗体及其用途

2017
- 2017-05-26 CN CN201780046023.8A patent/CN109476750B/zh active Active
- 2017-05-26 SI SI201731001T patent/SI3464361T1/sl unknown
- 2017-05-26 EP EP17728411.4A patent/EP3464361B1/en active Active
- 2017-05-26 PE PE2018003115A patent/PE20190970A1/es unknown
- 2017-05-26 TW TW111109284A patent/TWI814279B/zh active
- 2017-05-26 EP EP21200482.4A patent/EP3995511A1/en not_active Withdrawn
- 2017-05-26 LT LTEPPCT/US2017/034681T patent/LT3464361T/lt unknown
- 2017-05-26 RS RS20211552A patent/RS62726B1/sr unknown
- 2017-05-26 MX MX2018014630A patent/MX2018014630A/es unknown
- 2017-05-26 KR KR1020187037322A patent/KR102366355B1/ko active IP Right Grant
- 2017-05-26 TW TW106117521A patent/TWI761348B/zh active
- 2017-05-26 US US15/606,227 patent/US10519243B2/en active Active
- 2017-05-26 CR CR20180605A patent/CR20180605A/es unknown
- 2017-05-26 BR BR112018074468-9A patent/BR112018074468A2/pt unknown
- 2017-05-26 SG SG11201810522UA patent/SG11201810522UA/en unknown
- 2017-05-26 WO PCT/US2017/034681 patent/WO2017205742A1/en active Application Filing
- 2017-05-26 KR KR1020227005372A patent/KR20220028143A/ko active Application Filing
- 2017-05-26 NZ NZ748644A patent/NZ748644A/en unknown
- 2017-05-26 IL IL263223A patent/IL263223B2/en unknown
- 2017-05-26 JP JP2018561225A patent/JP2019523221A/ja not_active Withdrawn
- 2017-05-26 AR ARP170101447A patent/AR108611A1/es unknown
- 2017-05-26 UA UAA201812784A patent/UA123111C2/uk unknown
- 2017-05-26 PL PL17728411T patent/PL3464361T3/pl unknown
- 2017-05-26 RU RU2018146533A patent/RU2752049C2/ru active
- 2017-05-26 MY MYPI2018002113A patent/MY195442A/en unknown
- 2017-05-26 ES ES17728411T patent/ES2901722T3/es active Active
- 2017-05-26 SG SG10201914132RA patent/SG10201914132RA/en unknown
- 2017-05-26 AU AU2017271602A patent/AU2017271602A1/en active Pending
- 2017-05-26 HU HUE17728411A patent/HUE056670T2/hu unknown
- 2017-05-26 PT PT177284114T patent/PT3464361T/pt unknown
- 2017-05-26 CA CA3025347A patent/CA3025347A1/en active Pending
- 2017-05-26 HR HRP20211882TT patent/HRP20211882T1/hr unknown
2018
- 2018-02-21 US US15/901,560 patent/US10023645B1/en active Active
- 2018-07-16 US US16/036,691 patent/US10400041B2/en active Active
- 2018-11-22 PH PH12018502456A patent/PH12018502456A1/en unknown
- 2018-11-26 DO DO2018000258A patent/DOP2018000258A/es unknown
- 2018-11-26 CL CL2018003366A patent/CL2018003366A1/es unknown
- 2018-11-26 CO CONC2018/0012699A patent/CO2018012699A2/es unknown
- 2018-12-21 EC ECSENADI201894829A patent/ECSP18094829A/es unknown
2019
- 2019-09-03 US US16/559,504 patent/US10844131B2/en active Active
- 2019-10-21 US US16/659,209 patent/US10597460B2/en active Active
2020
- 2020-10-16 US US17/073,150 patent/US20210024642A1/en not_active Abandoned
2021
- 2021-05-21 US US17/327,264 patent/US20210277137A1/en not_active Abandoned
- 2021-12-03 CY CY20211101058T patent/CY1124806T1/el unknown
- 2021-12-30 US US17/566,149 patent/US20220119542A1/en not_active Abandoned
2022
- 2022-01-24 AR ARP220100135A patent/AR124692A2/es unknown
- 2022-02-18 JP JP2022023569A patent/JP7331179B2/ja active Active

Also Published As

Publication number	Publication date
SG11201810522UA (en)	2018-12-28
RU2018146533A (ru)	2020-06-29
IL263223B (en)	2022-11-01
CN109476750B (zh)	2022-02-01
EP3995511A1 (en)	2022-05-11
PH12018502456A1 (en)	2019-10-21
US20200010558A1 (en)	2020-01-09
US20190071509A1 (en)	2019-03-07
CR20180605A (es)	2020-01-13
CL2018003366A1 (es)	2019-03-15
US20180186889A1 (en)	2018-07-05
CA3025347A1 (en)	2017-11-30
EP3464361B1 (en)	2021-11-10
US10519243B2 (en)	2019-12-31
US20210277137A1 (en)	2021-09-09
US20210024642A1 (en)	2021-01-28
US10400041B2 (en)	2019-09-03
MY195442A (en)	2023-01-21
KR102366355B1 (ko)	2022-02-24
JP7331179B2 (ja)	2023-08-22
PL3464361T3 (pl)	2022-01-31
CN109476750A (zh)	2019-03-15
IL263223A (en)	2018-12-31
PT3464361T (pt)	2021-12-27
UA123111C2 (uk)	2021-02-17
RS62726B1 (sr)	2022-01-31
WO2017205742A1 (en)	2017-11-30
US10023645B1 (en)	2018-07-17
NZ748644A (en)	2023-05-26
US10597460B2 (en)	2020-03-24
TWI814279B (zh)	2023-09-01
TW201806971A (zh)	2018-03-01
BR112018074468A2 (pt)	2019-03-06
TW202229356A (zh)	2022-08-01
DOP2018000258A (es)	2019-02-15
LT3464361T (lt)	2022-01-10
CY1124806T1 (el)	2022-11-25
US20200040090A1 (en)	2020-02-06
ES2901722T3 (es)	2022-03-23
IL263223B2 (en)	2023-03-01
HRP20211882T1 (hr)	2022-03-04
US10844131B2 (en)	2020-11-24
KR20190014524A (ko)	2019-02-12
PE20190970A1 (es)	2019-07-09
JP2022068294A (ja)	2022-05-09
US20220119542A1 (en)	2022-04-21
JP2019523221A (ja)	2019-08-22
RU2752049C2 (ru)	2021-07-22
SI3464361T1 (sl)	2022-01-31
HUE056670T2 (hu)	2022-02-28
EP3464361A1 (en)	2019-04-10
US20170342159A1 (en)	2017-11-30
AU2017271602A1 (en)	2018-12-13
AR108611A1 (es)	2018-09-05
RU2018146533A3 (es)	2020-06-29
TWI761348B (zh)	2022-04-21
KR20220028143A (ko)	2022-03-08
MX2018014630A (es)	2019-06-10
AR124692A2 (es)	2023-04-26
ECSP18094829A (es)	2019-03-29
CO2018012699A2 (es)	2019-08-20

Publication	Publication Date	Title
HK1248718A1 (zh)	2018-10-19	抗cd40抗體及其用途
IL263223A (en)	2018-12-31	Antibodies against cd40 and their uses
HK1254861A1 (zh)	2019-07-26	抗lag3抗體及其用途
HK1251974A1 (zh)	2019-05-10	人源化抗cd40抗體及其用途
HK1252615A1 (zh)	2019-05-31	Il-8-結合抗體及其應用
HK1249911A1 (zh)	2018-11-16	抗muc16抗體及其應用
HK1250238A1 (zh)	2018-12-07	抗angptl8抗體及其用途
IL262095A (en)	2018-11-29	Anti-pacap antibodies and their use
HK1256381A1 (zh)	2019-09-20	抗pacap抗體及其用途
IL263273A (en)	2018-12-31	Antibodies against gitr and their uses
ZA201901935B (en)	2020-11-25	Anti-il-33 antibodies and uses thereof
GB201503387D0 (en)	2015-04-15	Anti-carbapenem antibodies and uses thereof
IL266049A (en)	2019-06-30	Antibodies against o1 and their uses
IL266082A (en)	2019-06-30	Anti-chikv antibodies and their use
IL264417A (en)	2019-02-28	Anti-o2 antibodies and their uses
HK1254240A1 (zh)	2019-07-12	抗羥腐胺賴氨酸抗體及其用途